Kezdőlap・Részvénylista・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Lezárt

SzektorEgészségügy

4.47 -2.4

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.41

Maximum

4.58

Fő mutatók
By Trading Economics
Bevétel	-187M -180M
Értékesítés	78M 234M
P/E Szektor átlag	8.634 57.002
Egy részvényre jutó nyereség	0.6
Profit margin	-76.91
Munkavállalók	900
EBITDA	-205M -156M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+117.86% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. okt. 28.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-148M 229M
Előző nyitás	6.87
Előző zárás	4.47

Hangulat hírek alapján

By Acuity

50%

154 / 340 Rangsor szerint Healthcare

Emergent BioSolutions Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 17. 19:56 UTC

News

Emergent BioSolutions faces investigations over financial disclosures, including a $191.3 million impairment charge, contributing to lower shares amid declining investor confidence.

2026. aug. 13. 19:51 UTC

Macro Event

Emergent BioSolutions Inc shares are roughly flat as jobless claims rise to 209,000, exceeding expectations. The stock remains below its 20-day moving average.

2026. aug. 12. 19:26 UTC

Emergent BioSolutions Inc gains amid broader market optimism following inflation data. The stock reached a session high before slightly pulling back.

2026. aug. 11. 22:56 UTC

Emergent BioSolutions Inc shares are trading lower in after-market hours. No specific news was identified to explain the movement.

2026. aug. 10. 19:51 UTC

News

Emergent BioSolutions shares are trading lower as H.C. Wainwright reduced its price target to $10.00, citing concerns over performance and outlook amid competitive pressures.

2026. aug. 7. 23:26 UTC

Emergent BioSolutions Inc shares rose in after-market trading, amid positive market sentiment and notable gains in major tech stocks. No specific news was identified.

2026. aug. 6. 23:41 UTC

Emergent BioSolutions traded roughly flat after market hours, with no specific news identified. The stock has declined significantly over the past month.

2026. aug. 5. 22:51 UTC

News

Emergent BioSolutions shares are lower in after-market hours following a Q2 net loss of $180.2 million and reduced full-year sales guidance.

2026. júl. 29. 19:56 UTC

Emergent BioSolutions Inc shares are trading higher Wednesday, reflecting gains since Tuesday's close, despite earlier fluctuations and broader market pressures.

2026. júl. 27. 18:46 UTC

Emergent BioSolutions Inc shares are higher amid a broader market trend, despite pulling back from earlier session highs. Crude oil prices have significantly declined.

2026. júl. 23. 19:36 UTC

Emergent BioSolutions Inc shares are lower, reflecting broader market trends amid negative earnings from major technology companies like Tesla and Alphabet.

Társak összehasonlítása

Árváltozás

Emergent BioSolutions Inc Előrejelzés

Célár

By TipRanks

117.86% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 10 USD 117.86%

Magas 10 USD

Alacsony 10 USD

1 Wall Street elemző 12 hónapos célárain alapulva a(z)Emergent BioSolutions Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

1 ratings

Vétel

Tartás

Eladás

1 Wall Street elemző célárain alapulva a(z)Emergent BioSolutions Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

154 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.